Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis 2型糖尿病患者每日1次使用利拉鲁肽(1.2 mg)治疗与每日2次使用艾塞那肽(10 μg)治疗的比较:一项间接治疗比较的meta分析

详细信息    查看全文

• 作者：Stephen M. Twigg ; Mirella M. Daja ; Beth A. O&rsquo ; leary and Michael A. Adena
• 刊名：Journal of Diabetes
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：8
• 期：6
• 页码：866-876
• 全文大小：1680K
• ISSN：1753-0407

文摘

Glucagon-like peptide-1 receptor agonists provide effective hyperglycemia management in patients with type 2 diabetes. In a randomized head-to-head trial, liraglutide 1.8 mg q.d. led to greater reductions in HbA1c than exenatide 10 μg b.i.d. There are no direct comparisons of liraglutide 1.2 mg q.d. and exenatide b.i.d.; therefore, in the present study, an indirect comparison and meta-analysis were undertaken.